Abstract
Intravitreal injection of triamcinolone acetonide (IVTA) has been used as an off-label strategy in the management of a wide range of edematous, neovascular and inflammatory retinal diseases. Despite the variable success rates achieved in each disease, a variety of adverse events have been reported. These may be associated with the intravitreal injection procedure (endophthalmitis, vitreous hemorrhage and retinal detachment), preservatives in the vehicle of the drug (intraocular toxicity and noninfectious endophthalmitis) and the corticosteroid itself (cataract, ocular hypertension and infection). This article aims to review the incidence and mechanisms of the potential adverse effects of IVTA injection.
